Spray of spirulina derivatives

Phase 2Small molecule

Spray of spirulina derivatives is one of 26 small molecule programs targeting Oral Mucositis. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Oral MucositisRecruiting

Oral MucositisPhase 2

Recruiting

Competition

Competitive Landscape

26 competitors in Oral Mucositis

#DrugCompanyPhaseTrials

Thalomid

Bristol-Myers Squibb

Approved

—2

MS Contin

HHikma Pharmaceuticals LLC

Approved

2 3

Levaquin

WWim Janssens

Approved

1 4

Alka-Seltzer

AAbbott

Approved

1 5

Catapres

Boehringer Ingelheim

Approved

—6

Acetadote

AArbor Pharmaceuticals, Inc.

Approved

—7

Heparin Sodium

BBaxter Healthcare Corporation

Approved

—8

Peridex

DDexcel Pharma Technologies Ltd.

Approved

—9

Betadine

BBecton, Dickinson and Company

Mycostatin

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Oral Mucositis1 trial

Spirulina-Derived Product Alleviates Oral Mucositis in Patients Undergoing Radiotherapy for Malignant Head and Neck Tumors

Recruiting·WWest China Hospital·Phase 2·NCT07040969·70 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Spray of spirulina derivatives. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Spray of spirulina derivatives compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Spray of spirulina derivatives. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — West China Hospital company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: WWest China Hospital

Spray of spirulina derivatives

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Oral Mucositis1 trial

References

Drug Info

Quick Facts

Related News